ACCP collaborates with ASHP on Oncology Pharmacy activities.

ASHP members, please visit www.rxcertifications.org to receive member pricing.

• Series Overview
• Program Content
• Faculty and Reviewers
• Financial Relationship Disclosures
• Target Audience and Learning Objectives
• Continuing Pharmacy Education Credit
• Specialty Recertification Credit
• Technical Requirements
• Commercial Support
• Fees

The 2023 ACCP/ASHP BCOP Clinical Sessions are part of the professional development programs for recertification of the Board Certified Oncology Pharmacist approved by the Board of Pharmacy Specialties (BPS) and jointly provided by ACCP and the American Society of Health-System Pharmacists (ASHP).

This educational series explores cutting-edge, contemporary therapeutic topics, and demonstrates scientifically sound clinical reasoning and decision-making. It employs learning activities designed to advance the participants' skills and abilities to critically evaluate the scientific evidence and to effectively incorporate into daily practice significant findings that lead to effective and safe patient care.

Release date: February 7, 2024
Specialty Recertification credit expiration date: December 17, 2024
ACPE credit expiration date: December 17, 2026

The 2023 ACCP/ASHP BCOP Clinical Sessions are offered in two presentations. The first presentation is focused on updates about amyloidosis and the second presentation is focused on the management of diffuse large b-cell lymphoma.

BCOP Clinical Session
Amyloidosis: Updates and Clinical Management
This session will evaluate recent literature and updates in the area of amyloidosis, focusing on the last 5 years and the impact on clinical management based on these updates. The speakers will cover the following subtopics: updates in AL amyloidosis management, new therapeutics in the pipeline and/or being used off-label in this area, updates in ATTR therapeutics, including vutirisan place in therapy, supportive care updates, and incorporating new guideline recommendations in practice. There will be discussion of case-based examples of these subtopics and how to incorporate these recommendations in clinical practice, and participants will identify strategies that institutions have identified on managing formulary incorporation of newer therapies, and strategies incorporated for cost, access, and adherence to novel therapies.

BCOP Clinical Session
Emerging Therapies and Clinical Controversies in the Management of Diffuse Large B-Cell Lymphoma
In this session, up-to-date literature on DLBCL treatment will be presented by subject matter experts in this field. There will be interactive patient cases that will be used to highlight how to best integrate new therapies and considerations regarding the identified therapeutic controversies that exist in DLBCL. In-depth discussion on recent literature and clinical pearls on managing the safety and administration of newer therapies will also be provided.

Disclosures 

Target Audience
These recertification activities are intended for the Board-Certified Oncology Pharmacist® (BCOP) and those interested in updates on amyloidosis or managing diffuse large b-cell lymphoma.

Learning Objectives
Learning Objectives 

The American College of Clinical Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

The American Society of Health-System Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education with Commendation.

The American College of Clinical Pharmacy and the American Society of Health-System Pharmacists are approved by BPS as a provider for the recertification of BCOP.

BCOP Clinical Session
Amyloidosis: Updates and Clinical Management
Activity Number: 0217-9999-23-076-H01-P
Contact Hours: 2.00
Activity Type: Application-Based Activity

BCOP Clinical Session
Emerging Therapies and Clinical Controversies in the Management of Diffuse Large B-Cell Lymphoma
Activity Number: Activity Number: 0217-9999-23-075-H01-P
Contact Hours: 2.00
Activity Type: Application-Based Activity

To be eligible to earn continuing pharmacy education credit, learners must purchase the product, review all content, successfully complete, submit and pass the web-based posttest associated with each module within the course by December 17, 2026. Only completed assessments will be eligible for credit; no partial or incomplete assessments will be processed.

National Association of Boards of Pharmacy - CPE Monitor Service

Provided through the collaborative efforts of the National Association of Boards of Pharmacy (NABP), the Accreditation Council for Pharmacy Education (ACPE), and ACPE-accredited providers, the CPE Monitor Service allows you to electronically keep track of continuing pharmacy education (CPE) credits from ACPE-accredited providers. ACPE-accredited providers, like ACCP, are responsible for transmitting this information to NABP to be stored in the CPE Monitor system. Statements of credit will be available at CPE Monitor, nabp.pharmacy/cpe-monitor-service/, within 2–3 business days after completion of this activity. For more information on CPE Monitor please visit nabp.pharmacy/cpe-monitor-service/.

To transfer these credits to CPE Monitor on your behalf your NABP e-Profile ID Number and date of birth must be listed on your ACCP account. To verify or update this information in your ACCP account, visit Licensure/Certification. Be sure to save your changes at the bottom of the page.

Some international pharmacists do not use the CPE Monitor service. To verify or update this information in your ACCP account, visit Licensure/Certification. Check the box “I am an international pharmacist or I am not licensed to practice in the United States, and do not have an NABP e-Profile ID.” Be sure to save your changes at the bottom of the page.

To be eligible to earn BCOP recertification credit, participants must purchase the recertification version of this course, review all content, successfully complete, submit and pass the web-based posttest associated with each module by December 17, 2024. Only completed assessments will be eligible for credit; no partial or incomplete assessments will be processed.

The passing point to earn BCOP recertification credit is based on an expert analysis of the assessment items in each posttest module. Any posttest submitted before the Specialty Recertification Credit posttest deadline that meets this passing point will earn BCOP recertification credits. These credits will be assigned as of the date of test submission.

All participants must have a Board of Pharmacy Specialties (BPS) board certification credential number, BPS ID Number, and a BPS expiration date on file with ACCP for reporting purposes. To verify or update this information in your ACCP account, visit Licensure/Certification. Be sure to save your changes at the bottom of the page.

For statements of recertification credit, visit www.bpsweb.org. Questions regarding the number of hours required for BCOP recertification should be directed to BPS at (202) 946-5026 or www.bpsweb.org.

• Internet browser
• Adobe Reader (available free)

The American College of Clinical Pharmacy does not solicit or accept external commercial/financial support for its continuing pharmacy education activities. No commercial/financial support has been solicited or accepted for this activity.